Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Hitomi, Hayashi, Hidetoshi, Iwasa, Tsutomu, Hasegawa, Yoshikazu, Takeda, Masayuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559906/
https://www.ncbi.nlm.nih.gov/pubmed/28848674
http://dx.doi.org/10.1136/esmoopen-2016-000104
_version_ 1783257598210867200
author Sakai, Hitomi
Hayashi, Hidetoshi
Iwasa, Tsutomu
Hasegawa, Yoshikazu
Takeda, Masayuki
Nakagawa, Kazuhiko
author_facet Sakai, Hitomi
Hayashi, Hidetoshi
Iwasa, Tsutomu
Hasegawa, Yoshikazu
Takeda, Masayuki
Nakagawa, Kazuhiko
author_sort Sakai, Hitomi
collection PubMed
description Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficacy against leptomeningeal carcinomatosis (LMC) derived from NSCLC resistant to first-generation and second-generation EGFR-TKIs. We now report the case of a patient aged 70 years with symptomatic LMC derived from NSCLC with the T790M mutation of EGFR who showed a clinical and radiographic response to osimertinib.
format Online
Article
Text
id pubmed-5559906
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55599062017-08-28 Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR Sakai, Hitomi Hayashi, Hidetoshi Iwasa, Tsutomu Hasegawa, Yoshikazu Takeda, Masayuki Nakagawa, Kazuhiko ESMO Open Original Research Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficacy against leptomeningeal carcinomatosis (LMC) derived from NSCLC resistant to first-generation and second-generation EGFR-TKIs. We now report the case of a patient aged 70 years with symptomatic LMC derived from NSCLC with the T790M mutation of EGFR who showed a clinical and radiographic response to osimertinib. BMJ Publishing Group 2017-03-07 /pmc/articles/PMC5559906/ /pubmed/28848674 http://dx.doi.org/10.1136/esmoopen-2016-000104 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Original Research
Sakai, Hitomi
Hayashi, Hidetoshi
Iwasa, Tsutomu
Hasegawa, Yoshikazu
Takeda, Masayuki
Nakagawa, Kazuhiko
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title_full Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title_fullStr Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title_full_unstemmed Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title_short Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
title_sort successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the t790m mutation of egfr
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559906/
https://www.ncbi.nlm.nih.gov/pubmed/28848674
http://dx.doi.org/10.1136/esmoopen-2016-000104
work_keys_str_mv AT sakaihitomi successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr
AT hayashihidetoshi successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr
AT iwasatsutomu successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr
AT hasegawayoshikazu successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr
AT takedamasayuki successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr
AT nakagawakazuhiko successfulosimertinibtreatmentforleptomeningealcarcinomatosisfromlungadenocarcinomawiththet790mmutationofegfr

Ejemplares similares